Amgen AMGN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.82B+36.5% | $1.33B-58.6% | $3.22B+125% | $1.43B-17.2% | $1.73B+176% | ||
| $1.12B-1.4% | $1.13B-13.4% | $1.31B-2.5% | $1.34B-3.3% | $1.39B-0.7% | ||
| $75M-40.0% | $125M-1.6% | $127M-19.1% | $157M+84.7% | $85M-36.6% | ||
| -$176M-826% | -$19M+36.7% | -$30M+92.9% | -$422M-68.8% | -$250M+25.1% | ||
| $0— | —— | $400M— | —— | $800M+2,567% | ||
| -$413M-138% | $1.08B— | $0-100% | $515M-60.6% | $1.31B+377% | ||
| -$18M+84.9% | -$119M+50.4% | -$240M-0.4% | -$239M+17.0% | -$288M+10.8% | ||
| $571M— | —— | —— | $589M+18.5% | $497M— | ||
| -$959M-228% | $749M+475% | -$200M-124% | $824M+194% | -$874M-220% | ||
| -$8M-101% | $577M+104% | $283M+37.4% | $206M+2.5% | $201M+1,336% | ||
| -$75M+1.3% | -$76M-660% | -$10M— | $0+100% | -$78M— | ||
| $67M+127% | -$250M-993% | $28M+21.7% | $23M-54.0% | $50M+31.6% | ||
| $71M+119% | -$365M— | —— | -$2.42B-2,424% | $104M— | ||
| -$143M— | —— | $1.97B— | —— | $1.3B+248% | ||
| $2.19B+36.6% | $1.6B-65.8% | $4.68B+105% | $2.28B+63.9% | $1.39B-70.8% | ||
| $712M+10.9% | $642M+47.2% | $436M+18.2% | $369M-10.2% | $411M+10.8% | ||
| $4M— | —— | —— | $20M-44.4% | $36M— | ||
| -$716M-3.3% | -$693M-67.4% | -$414M-6.4% | -$389M+13.0% | -$447M-11.2% | ||
| $1.36B+5.8% | $1.28B+0.1% | $1.28B+0.2% | $1.28B+0.1% | $1.28B+6.1% | ||
| $3.96B— | —— | —— | —— | $0— | ||
| $833M— | $0-100% | $1.5B+50.0% | $1B-60.0% | $2.5B— | ||
| -$104M— | —— | —— | -$92M-241% | -$27M-1,250% | ||
| $1.44B+217% | -$1.23B+57.0% | -$2.85B-6.7% | -$2.67B+34.9% | -$4.11B-192% | ||
| $2.91B+1,021% | -$316M— | —— | -$782M+75.3% | -$3.16B-207% | ||
| -$839M— | —— | $1.18B+88.8% | $627M+29.0% | $486M-26.1% | ||
| $71M-5.3% | $75M+1.4% | $74M-19.6% | $92M+31.4% | $70M— | ||
| -$8M-101% | $577M+104% | $283M+37.4% | $206M+2.5% | $201M+1,336% | ||
| $67M+127% | -$250M-993% | $28M+21.7% | $23M-54.0% | $50M+31.6% | ||
| $4M— | —— | —— | $20M-44.4% | $36M— | ||
| $233M— | $0-100% | $81M-73.1% | $301M0.0% | $301M— | ||
| -$104M— | —— | —— | -$92M-241% | -$27M-1,250% | ||
| -$143M— | —— | $1.97B— | —— | $1.3B+248% | ||
| $1.48B+53.7% | $961M-77.4% | $4.25B+122% | $1.91B+95.0% | $980M-77.7% | ||
| $1.48B+53.7% | $961M-77.4% | $4.25B+122% | $1.91B+95.0% | $980M-77.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amgen generate?
- Amgen (AMGN) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Amgen's free cash flow?
- After $2.2B of capital expenditures, Amgen's free cash flow was $8.6B over the trailing twelve months, down 21.2% year over year.
- Where does Amgen's cash flow data come from?
- Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
